Long-term Survival After Endoscopic Resection For Gastric Cancer: Real-world Evidence From a Multicenter Prospective Cohort

医学 癌症存活率 内科学 前瞻性队列研究 癌症 队列研究 普通外科
作者
Haruhisa Suzuki,Hiroyuki Ono,Toshiaki Hirasawa,Yoji Takeuchi,Kenji Ishido,Shu Hoteya,Tomonori Yano,Shinji Tanaka,Yosuke Toya,Masahiro Nakagawa,Takashi Toyonaga,Kenichi Takemura,Kingo Hirasawa,Mitsuru Matsuda,Hironori Yamamoto,Yosuke Tsuji,Satoru Hashimoto,Yuki Maeda,Tsuneo Oyama,Ryuta Takenaka
出处
期刊:Clinical Gastroenterology and Hepatology [Elsevier BV]
卷期号:21 (2): 307-318.e2 被引量:53
标识
DOI:10.1016/j.cgh.2022.07.029
摘要

We aimed to clarify the long-term outcomes of endoscopic resection (ER) for early gastric cancers (EGCs) based on pathological curability in a multicenter prospective cohort study.We analyzed the long-term outcomes of 9054 patients with 10,021 EGCs undergoing ER between July 2010 and June 2012. Primary endpoint was the 5-year overall survival (OS). The hazard ratio for all-cause mortality was calculated using the Cox proportional hazards model. We also compared the 5-year OS with the expected one calculated for the surgically resected patients with EGC. If the lower limit of the 95% confidence interval (CI) of the 5-year OS exceeded the expected 5-year OS minus a margin of 5% (threshold 5-year OS), ER was considered to be effective. Pathological curability was categorized into en bloc resection, negative margins, and negative lymphovascular invasion: differentiated-type, pT1a, ulcer negative, ≤2 cm (Category A1); differentiated-type, pT1a, ulcer negative, >2 cm or ulcer positive, ≤3 cm (Category A2); undifferentiated-type, pT1a, ulcer negative, ≤2 cm (Category A3); differentiated-type, pT1b (SM1), ≤3 cm (Category B); or noncurative resections (Category C).Overall, the 5-year OS was 89.0% (95% CI, 88.3%-89.6%). In a multivariate analysis, no significant differences were observed when the hazard ratio of Categories A2, A3, and B were compared with that of A1. In all the pathological curability categories, the lower limit of the 95% CI for the 5-year OS exceeded the threshold 5-year OS.ER can be recommended as a standard treatment for patients with EGCs fulfilling Category A2, A3, and B, as well as A1 (UMIN Clinical Trial Registry, UMIN000005871).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丘比特的应助被关琦采纳,获得10
刚刚
ph完成签到,获得积分10
刚刚
咿呀咿呀哟的应助被黄兆强采纳,获得10
刚刚
go转瓦发布了新的文献求助10
1秒前
Hello的应助被小学僧采纳,获得10
1秒前
桐桐的应助被昊仔采纳,获得10
2秒前
2秒前
清栀发布了新的文献求助10
2秒前
HAHA完成签到,获得积分10
2秒前
2秒前
zeal发布了新的文献求助10
3秒前
dd99081完成签到,获得积分10
4秒前
郑粥粥完成签到,获得积分10
4秒前
4秒前
4秒前
4秒前
ahui完成签到,获得积分10
5秒前
HAI完成签到,获得积分10
5秒前
安安完成签到,获得积分10
5秒前
梨涡远点啊完成签到,获得积分10
6秒前
AA完成签到,获得积分20
6秒前
Akim的应助被22采纳,获得10
6秒前
6秒前
共享精神的应助被浏阳河采纳,获得10
6秒前
向媛完成签到,获得积分10
7秒前
7秒前
Bella发布了新的文献求助10
7秒前
白耀庭发布了新的文献求助10
8秒前
免疫线李亚楠完成签到,获得积分10
8秒前
superchen完成签到,获得积分10
8秒前
8秒前
顺利的小陈完成签到,获得积分10
9秒前
白鹿完成签到,获得积分20
9秒前
yunian发布了新的文献求助10
9秒前
JamRoss完成签到,获得积分10
9秒前
五月花完成签到,获得积分10
9秒前
Anonymous的应助被嘉欣采纳,获得20
9秒前
10秒前
10秒前
今后的应助被嗯嗯采纳,获得10
10秒前
高分求助中
(应助此贴封号)通过应助OA文献获取积分 10000
Rosenblum, Global Change Biology 800
Organizational Behavior 510
Management and the Arts 510
Convergent and bidirectional strategies towards the total synthesis of hemibrevetoxin B 300
Geschichtliche Grundbegriffe (GGB), Band 5: Pro–Soz 300
Die Religion in Geschichte und Gegenwart (RGG), 4. Auflage, Band 7: R–S 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 内科学 物理 有机化学 化学工程 生物化学 复合材料 光电子学 细胞生物学 心理学 量子力学 催化作用 物理化学 电极
热门帖子
关注 科研通微信公众号,转发送积分 7798639
求助须知:如何正确求助?哪些是违规求助? 9333691
关于积分的说明 20463431
捐赠科研通 7389569
什么是DOI,文献DOI怎么找? 3325702
关于科研通互助平台的介绍 2473024
邀请新用户注册赠送积分活动 2343172